The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 68 394-424

[2] Ferlay J(2007)The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer J Thorac Oncol 2 603-612

[3] Soerjomataram I(2013)Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer Chest 144 1253-1260

[4] Siegel RL(2017)Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry J Clin Oncol 35 1162-1170

[5] Torre LA(2017)Improved lymph node staging in early-stage lung cancer in the national cancer database Ann Thorac Surg 104 1805-1814

[6] Jemal A(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 3552-3559

[7] Rusch VW(2012)Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes Eur J Cardiothorac Surg 41 19-24

[8] Crowley J(2011)Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer Thorax 66 287-293

[9] Giroux DJ(2016)Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer World J Surg Oncol 14 295-33918

[10] Li ZM(2015)Lymph node ratio is a prognostic factor for non-small cell lung cancer Oncotarget 6 33912-1170

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 68 394-424

[2] Ferlay J(2007)The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer J Thorac Oncol 2 603-612

[3] Soerjomataram I(2013)Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer Chest 144 1253-1260

[4] Siegel RL(2017)Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry J Clin Oncol 35 1162-1170

[5] Torre LA(2017)Improved lymph node staging in early-stage lung cancer in the national cancer database Ann Thorac Surg 104 1805-1814

[6] Jemal A(2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 3552-3559

[7] Rusch VW(2012)Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes Eur J Cardiothorac Surg 41 19-24

[8] Crowley J(2011)Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer Thorax 66 287-293

[9] Giroux DJ(2016)Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer World J Surg Oncol 14 295-33918

[10] Li ZM(2015)Lymph node ratio is a prognostic factor for non-small cell lung cancer Oncotarget 6 33912-1170